Eli Lilly to Offer Experimental GLP-1 Retatrutide for Compassionate Use — Who Qualifies?

Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Lilly will not file retatrutide with the FDA until early 2027. What that delay means for cost, insurance coverage, and patients considering waiting.

Eli Lilly to Offer Experimental GLP-1 Retatrutide for Compassionate Use — Who Qualifies?

Eli Lilly, the drugmaker behind the GLP-1 drugs Mounjaro and Zepbound, will allow a limited number of adults with severe obesity to seek early access to retatrutide , its experimental weight loss drug, according to original reporting from STAT , a health and life science news publication.e60dc2a1-f33c-4a05-9b50-8e3e8e597629720dcee3-0982-4e56-8e3c-1ba7d01bc5c8 The decision comes after STAT revealed that the company had provided the unapproved med…

Eli Lilly to offer early access to next-gen obesity drug to some patients - Regional Media News

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval. "For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's gui…

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early ​access to its experimental obesity drug, retatrutide, before ‌its U.S. FDA approval. "For a limited number of patients...

Eli Lilly to allow more patients to apply for special access to unapproved obesity drug

After a well-connected patient got compassionate use access to the weight loss drug, doctors asked Lilly for similar access. Monday, Lilly agreed to do so.